6-K 1 a7730e.htm RESULT OF AGM a7730e
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of April 2025
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
Result of AGM
 
 
11 April 2025
 
 
 
Results of Annual General Meeting held on 11 April 2025
 
 
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.
 
 
 
Resolution
 
Votes for
 
% of votes cast
 
Votes against
 
% of votes cast
 
Votes cast in total
 
Total votes cast as a % of issued share capital
 
Votes withheld
 
1
 
To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2024
 
1,192,725,049
 
99.89
 
1,302,321
 
0.11
 
1,194,027,370
 
77.00
 
3,895,442
 
2
 
To confirm the 2024 interim dividends
 
1,195,017,493
 
99.91
 
1,103,545
 
0.09
 
1,196,121,038
 
77.14
 
1,801,779
 
3
 
To re-appoint PricewaterhouseCoopers LLP as Auditor
 
1,188,274,693
 
99.35
 
7,772,140
 
0.65
 
1,196,046,833
 
77.13
 
1,875,089
 
4
 
To authorise the Directors to agree the remuneration of the Auditor
 
1,194,967,897
 
99.91
 
1,035,521
 
0.09
 
1,196,003,418
 
77.13
 
1,919,068
 
5a
 
To re-elect Michel Demaré as a Director
 
1,192,597,854
 
99.72
 
3,348,956
 
0.28
 
1,195,946,810
 
77.13
 
1,975,799
 
5b
 
To re-elect Pascal Soriot as a Director
 
1,194,161,249
 
99.85
 
1,828,809
 
0.15
 
1,195,990,058
 
77.13
 
1,932,568
 
5c
 
To re-elect Aradhana Sarin as a Director
 
1,193,240,137
 
99.77
 
2,730,661
 
0.23
 
1,195,970,798
 
77.13
 
1,951,782
 
5d
 
To re-elect Philip Broadley as a Director
 
1,192,344,687
 
99.70
 
3,578,792
 
0.30
 
1,195,923,479
 
77.12
 
1,999,129
 
5e
 
To re-elect Euan Ashley as a Director
 
1,193,753,030
 
99.82
 
2,163,488
 
0.18
 
1,195,916,518
 
77.12
 
2,006,023
 
5f
 
To elect Birgit Conix as a Director
 
1,195,603,172
 
99.97
 
315,680
 
0.03
 
1,195,918,852
 
77.12
 
2,003,690
 
5g
 
To elect Rene Haas as a Director
 
1,173,872,808
 
98.16
 
22,033,446
 
1.84
 
1,195,906,254
 
77.12
 
2,016,215
 
5h
 
To elect Karen Knudsen as a Director
 
1,195,604,027
 
99.97
 
301,466
 
0.03
 
1,195,905,493
 
77.12
 
2,017,116
 
5i
 
To re-elect Diana Layfield as a Director
 
1,195,604,497
 
99.97
 
300,003
 
0.03
 
1,195,904,500
 
77.12
 
2,018,109
 
5j
 
To re-elect Anna Manz as a Director
 
1,194,823,605
 
99.91
 
1,048,387
 
0.09
 
1,195,871,992
 
77.12
 
2,050,618
 
5k
 
To re-elect Sheri McCoy as a Director
 
1,149,796,685
 
96.15
 
46,101,055
 
3.85
 
1,195,897,740
 
77.12
 
2,024,865
 
5l
 
To re-elect Tony Mok as a Director
 
1,195,574,262
 
99.97
 
310,802
 
0.03
 
1,195,885,064
 
77.12
 
2,037,477
 
5m
 
To re-elect Nazneen Rahman as a Director
 
1,193,299,249
 
99.79
 
2,566,024
 
0.21
 
1,195,865,273
 
77.12
 
2,057,343
 
5n
 
To re-elect Marcus Wallenberg as a Director
 
980,843,680
 
83.11
 
199,351,215
 
16.89
 
1,180,194,895
 
76.11
 
17,727,254
 
6
 
To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2024
 
1,152,784,239
 
96.40
 
43,097,131
 
3.60
 
1,195,881,370
 
77.12
 
2,041,421
 
7
 
To authorise limited political donations
 
1,152,744,556
 
96.90
 
36,841,029
 
3.10
 
1,189,585,585
 
76.72
 
8,336,892
 
8
 
To authorise the Directors to allot shares
 
1,108,802,235
 
92.72
 
87,039,743
 
7.28
 
1,195,841,978
 
77.12
 
2,080,506
 
9
 
To authorise the Directors to disapply pre-emption rights
 
1,057,501,935
 
88.45
 
138,089,003
 
11.55
 
1,195,590,938
 
77.10
 
2,331,672
 
10
 
To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
 
1,011,405,311
 
84.89
 
179,961,211
 
15.11
 
1,191,366,522
 
76.83
 
6,556,062
 
11
 
To authorise the Company to purchase its own shares
 
1,186,436,265
 
99.24
 
9,028,112
 
0.76
 
1,195,464,377
 
77.10
 
2,458,408
 
12
 
To reduce the notice period for general meetings
 
1,109,717,539
 
92.81
 
85,989,258
 
7.19
 
1,195,706,797
 
77.11
 
2,216,021
 
 
 
Deborah DiSanzo and Andreas Rummelt retired from the Board at the conclusion of the AGM. For the purposes of section 430(2B) of the Companies Act 2006, they will receive their pro-rata entitlement to non-executive director fees for the month of April 2025. No other remuneration payment or payment for loss of office will be made.
 
A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
 
Issued capital
 
As at 9 April 2025, the number of issued shares of the Company was 1,550,636,615 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
 
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
 
 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
Adrian Kemp
Company Secretary
AstraZeneca PLC
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
Date: 11 April 2025
 
 
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary